Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.43
FOLD's Cash to Debt is ranked higher than
69% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. FOLD: 5.43 )
FOLD' s 10-Year Cash to Debt Range
Min: 4.97   Max: No Debt
Current: 5.43

Equity to Asset 0.31
FOLD's Equity to Asset is ranked higher than
54% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. FOLD: 0.31 )
FOLD' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.84
Current: 0.31

0.28
0.84
F-Score: 2
Z-Score: -1.72
M-Score: 21.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -17680.72
FOLD's Operating margin (%) is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. FOLD: -17680.72 )
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72   Max: -11.42
Current: -17680.72

-17680.72
-11.42
Net-margin (%) -16427.82
FOLD's Net-margin (%) is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. FOLD: -16427.82 )
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82   Max: -10.2
Current: -16427.82

-16427.82
-10.2
ROE (%) -130.34
FOLD's ROE (%) is ranked higher than
54% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. FOLD: -130.34 )
FOLD' s 10-Year ROE (%) Range
Min: -150.08   Max: -9.14
Current: -130.34

-150.08
-9.14
ROA (%) -46.75
FOLD's ROA (%) is ranked higher than
61% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. FOLD: -46.75 )
FOLD' s 10-Year ROA (%) Range
Min: -1350.9   Max: -7.69
Current: -46.75

-1350.9
-7.69
ROC (Joel Greenblatt) (%) -1557.79
FOLD's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. FOLD: -1557.79 )
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2144.32   Max: -167.08
Current: -1557.79

-2144.32
-167.08
Revenue Growth (%) -30.70
FOLD's Revenue Growth (%) is ranked higher than
64% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. FOLD: -30.70 )
FOLD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -2.6
Current: -30.7

EBITDA Growth (%) -14.80
FOLD's EBITDA Growth (%) is ranked higher than
70% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. FOLD: -14.80 )
FOLD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 82.8
Current: -14.8

0
82.8
EPS Growth (%) -16.30
FOLD's EPS Growth (%) is ranked higher than
71% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. FOLD: -16.30 )
FOLD' s 10-Year EPS Growth (%) Range
Min: -85.2   Max: 59.5
Current: -16.3

-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

FOLD Guru Trades in Q3 2013

Jim Simons 302,600 sh (+74.26%)
RS Investment Management 2,794,439 sh (+10.78%)
Chuck Royce 515,700 sh (-27.94%)
» More
Q4 2013

FOLD Guru Trades in Q4 2013

Jim Simons 399,401 sh (+31.99%)
RS Investment Management 2,797,339 sh (+0.1%)
Chuck Royce 355,700 sh (-31.03%)
» More
Q1 2014

FOLD Guru Trades in Q1 2014

Charles Brandes 48,100 sh (New)
RS Investment Management 2,816,739 sh (+0.69%)
Chuck Royce 313,700 sh (-11.81%)
Jim Simons 121,000 sh (-69.7%)
» More
Q2 2014

FOLD Guru Trades in Q2 2014

George Soros 70,500 sh (New)
Charles Brandes Sold Out
RS Investment Management Sold Out
Jim Simons Sold Out
Chuck Royce 283,700 sh (-9.56%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.82 - $3.03 $ 6.94198%70500
Charles Brandes 2014-06-30 Sold Out $1.82 - $3.03 $ 6.94198%0
Charles Brandes 2014-03-31 New Buy$2.04 - $3.08 $ 6.94178%48100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.10
FOLD's P/B is ranked lower than
52% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. FOLD: 14.10 )
FOLD' s 10-Year P/B Range
Min: 0.64   Max: 14.38
Current: 14.1

0.64
14.38
P/S 232.40
FOLD's P/S is ranked lower than
56% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 19.49 vs. FOLD: 232.40 )
FOLD' s 10-Year P/S Range
Min: 0.71   Max: 290
Current: 232.4

0.71
290
EV-to-EBIT -7.39
FOLD's EV-to-EBIT is ranked lower than
52% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FOLD: -7.39 )
FOLD' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 0.8
Current: -7.39

0.1
0.8
Current Ratio 7.11
FOLD's Current Ratio is ranked higher than
84% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. FOLD: 7.11 )
FOLD' s 10-Year Current Ratio Range
Min: 3.46   Max: 18.26
Current: 7.11

3.46
18.26
Quick Ratio 7.11
FOLD's Quick Ratio is ranked higher than
85% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. FOLD: 7.11 )
FOLD' s 10-Year Quick Ratio Range
Min: 3.46   Max: 18.26
Current: 7.11

3.46
18.26

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.50
FOLD's Price/Tangible Book is ranked higher than
66% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. FOLD: 20.50 )
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 8.91
Current: 20.5

0.96
8.91
Price/Median PS Value 26.80
FOLD's Price/Median PS Value is ranked higher than
64% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. FOLD: 26.80 )
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 26.11
Current: 26.8

0.09
26.11
Forward Rate of Return (Yacktman) -15.67
FOLD's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. FOLD: -15.67 )
FOLD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 86.4   Max: 734.4
Current: -15.67

86.4
734.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany
Amicus Therapeutics, Inc. was incorporated on February 4, 2002 in Delaware. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. The Company is focused on the development of pharmacological chaperones as monotherapies and in combination with enzyme replacement therapy (ERT), the current standard of treatment for Fabry and other lysosomal storage diseases. In 2012, it is advancing two monotherapy programs for genetic diseases: Migalastat HCl for patients with Fabry disease identified as having alpha-galactosidase A (alpha-Gal A) mutations amenable to chaperone therapy, and AT3375 for Parkinson's disease in Gaucher disease carriers and potentially the broader Parkinson's population. Its pharmacological chaperone-ERT combination programs for 2012 include: Migalastat HCl co-administered with ERT for patients with Fabry disease receiving ERT treatment with any genetic mutation, AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, AT3375 and afegostat tartrate co-administered with ERT for Gaucher disease, and Several new, undisclosed pharmacological chaperone programs focused on the combination of chaperones with ERTs for additional lysosomal storage diseases. The Company's novel approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein; increasing the stability of the protein and helping it fold into the correct three-dimensional shape. Its product candidate, migalastat HCl for Fabry disease, is in late Phase 3 development. It is developing and commercializing migalastat HCl with an affiliate of GlaxoSmithKline PLC (GSK) pursuant to a License and Collaboration Agreement entered into in October 2010. Its partnership with GSK allows it to utilize GSK's significant expertise in clinical, regulatory, commercial and manufacturing matters in the development of migalastat HCl. In addition, it is conducting another Phase 2 co-administration study evaluating its pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with ERT in Pompe patients. Unlike migalastat HCl, it owns rights to the development of AT2220. In addition to its patents and trade secrets, The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design and AMICUS THERAPEUTICS. Its competitors include Sanofi Aventis, Shire, Actelion, Ltd. and Protalix Biotherapeutics. The Company's product candidates, including migalastat HCl, and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Our Partners
Morning Market Movers Aug 29 2014 - BENZINGA

More From Other Websites
Amicus Therapeutics (FOLD) Stock Rises on High Volume Aug 28 2014
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb Aug 28 2014
Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 10.3% Aug 28 2014
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As Aug 27 2014
Amicus Therapeutics Hits 52-Week High on Migalastat Data Aug 27 2014
Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's Strong On High Relative Volume Stock Aug 22 2014
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Aug 21 2014
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue? Aug 21 2014
Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 20.4% Aug 21 2014
Amicus Therapeutics’ Successful Drug Trial Results in Short-Lived High Aug 20 2014
Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today Aug 20 2014
US STOCKS-Wall St set to dip after retailer results; Fed minutes due Aug 20 2014
Amicus Therapeutic’s Fabry treatment meets goals in late-stage trial Aug 20 2014
AMICUS THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Aug 20 2014
Amicus Releases Positive Study Results On Rare Disease Drug Aug 20 2014
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win Aug 20 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012 Aug 20 2014
AMICUS THERAPEUTICS INC Financials Aug 15 2014
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates Aug 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK